BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33141608)

  • 21. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
    Chan WM; Lai TY; Lai RY; Liu DT; Lam DS
    Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.
    Karakus SH; Basarir B; Pinarci EY; Kirandi EU; Demirok A
    Eye (Lond); 2013 May; 27(5):612-20. PubMed ID: 23519277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
    Lim SH; Chang W; Sagong M
    Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
    Fujita K; Yuzawa M; Mori R
    Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
    Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
    Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy.
    Chung CY; Chan YY; Li KKW
    Ophthalmologica; 2018; 240(1):37-44. PubMed ID: 29566395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Demirel S; Özcan G; Yanık Ö; Batıoğlu F; Özmert E
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):905-912. PubMed ID: 30617579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological and Functional Changes Immediately After Half-Time Photodynamic Therapy in Patients With Central Serous Chorioretinopathy.
    Muslubas IS; Ersoz MG; Hocaoglu M; Arf S; Karacorlu M
    Ophthalmic Surg Lasers Imaging Retina; 2018 Dec; 49(12):932-940. PubMed ID: 30566700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
    Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C
    Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
    Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
    Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
    Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.
    van Rijssen TJ; Singh SR; van Dijk EHC; Rasheed MA; Vupparaboina KK; Boon CJF; Chhablani J
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1191-1197. PubMed ID: 32170365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
    Demircan A; Yesilkaya C; Alkin Z
    Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing Half-Dose Photodynamic Therapy with Subthreshold Micropulse Laser for the Treatment of Central Serous Chorioretinopathy.
    Brelen ME; Ho M; Li S; Ng DSC; Yip YWY; Lee WS; Chen LJ; Young AL; Tham CC; Pang CP
    Ophthalmol Retina; 2024 May; 8(5):490-498. PubMed ID: 37956794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.
    Iacono P; Tedeschi M; Boccassini B; Chiaravalloti A; Varano M; Parravano M
    Retina; 2019 May; 39(5):980-987. PubMed ID: 29346241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
    Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.